Immune Resistance and EGFR Antagonists in Colorectal Cancer

Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy in patients with RAS wild type metastatic colorectal cancer (mCRC) has revolutionized the treatment of CRC, but with less results than initially envisaged. In recent years, the discovery of multipl...

Descripción completa

Detalles Bibliográficos
Autores principales: Giordano, Guido, Remo, Andrea, Porras, Almudena, Pancione, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721348/
https://www.ncbi.nlm.nih.gov/pubmed/31370270
http://dx.doi.org/10.3390/cancers11081089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721348/
https://www.ncbi.nlm.nih.gov/pubmed/31370270
http://dx.doi.org/10.3390/cancers11081089

Ejemplares similares